Access and Uptake of Direct Acting Antiviral Medicines in the UK and selected European countries

This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines. For example, Portugal, Belgium and Germany have now treated over a quarter of their estimated prevalent patients. By contrast, the trend in the UK has been one of slower and lower levels of access.